Ron DiGiaimo

Chairman of the Board for R3/RCCS/RC Billing/Regents Health Resources aka Roncology - Ron & Oncology

[Ron DiGiaimo @DigiaimoRon]

https://t.co/LC9Hhwq5eY Please check out this article meant to help #RTTs in their first five years. @OfficialRCCSInc @ASRT @RegentsHealth #radiationtherapy

[Oncology Brothers @OncBrothers]

Lung Cancer Highlights from #ESMO26 w/ @HosseinBorghaei

✅ #DeLLphi305
✅ #SAFFRON
✅ #KRASCENDO1
✅ #PERSEE

Full 🗣️
⭐️ https://t.co/4oEXIivwIZ
⭐️“Oncology Brothers” podcast

#OncTwitter #lcsm @OncoAlert @OncUpdates @myESMO

[Matt Spraker @SprakerMDPhD]

All due respect to @BrendonStilesMD

This is probably the most surgeon-y figure I've ever seen

[Ron DiGiaimo @DigiaimoRon]

Please look into donating to this go fund me to stop insurers from taking away coverage of LDRT: https://t.co/eIU302nlw6 @EvanThomas84 @KoneruMd @Tarita_ThomasMD

[Ron DiGiaimo @DigiaimoRon]

@twominute00 @toddscarbrough Ha

[Ron DiGiaimo @DigiaimoRon]

Sally Kozak
Deputy Secretary
Pennsylvania Department of Human Services
Office of Medical Assistance Programs Commonwealth of Pennsylvania, Department of Human Services
625 Forster Street, Room 515
Harrisburg, PA 17120
[email protected]

Re: Urgent Request to Update and Correct Medicaid Payment Rates for Radiation Oncology Services – CPT® Codes 77387, 77402, 77407, and 77412

Dear Deputy Secretary:

I am writing to you in my capacity as Chairman of R3 with clients in Pennsylvania to express grave concern regarding the current Pennsylvania reimbursement rates for essential radiation oncology treatment delivery and guidance services. These outdated rates are unsustainable.

The rates for the revised radiation treatment codes are as follows:

· CPT 77387 (IGRT): $15.73
· CPT 77402 (Rad treatment 1): $60.36
· CPT 77407 (Rad treatment 2): $227.68
· CPT 77412 (Rad treatment 3): $325.80

These rates are catastrophically low and do not come close to covering the actual costs of delivering safe, precise, and effective radiation therapy. Radiation oncology requires substantial capital investment in linear accelerators, imaging systems, quality assurance, physics support, and highly trained clinical staff. At these reimbursement levels, practices cannot absorb the ongoing operational expenses, leading to reduced capacity, delayed treatments, or complete discontinuation of services for Pennsylvania patients in many communities. This directly jeopardizes patient outcomes in a vulnerable population that already faces barriers to care.

By comparison, national Medicare benchmarks for these same services (updated effective January 1, 2026.

· CPT 77387 (professional component only): approximately $36.74

· CPT 77402 (Level 1): approx $79.49 (PFS) to $104.24 (HOPPS)

· CPT 77407 (Level 2): approx $317.64 (PFS) to $394.05 (HOPPS)

· CPT 77412 (Level 3): approx $391.46 (PFS) to $564.51 (HOPPS)

Pennsylvania’s rates are lower than Medicare’s creating an untenable disparity. Many commercial payers reimburse at even higher levels. These national rates, while not extravagant, at least allow practices to maintain operations and invest in modern technology required for accurate, image-guided treatment.

The situation is urgent. Radiation therapy is a cornerstone of curative and palliative cancer care in which approximately 60% of cancer patients receive radiation therapy at some point in their treatment journey. Inadequate reimbursement threatens provider participation in Pennsylvania networks, reduces geographic access.

We respectfully request that your appropriate team immediately review and align Pennsylvania payment rates for CPT codes 77387, 77402, 77407, and 77412 with national Medicare benchmarks (or a reasonable cost-based equivalent) to ensure continued access to these critical services.

Sincerely,

Ron DiGiaimo MBA FACHE
RCCS R3source Health: RCCS | Regents | RC Billing

@OfficialRCCSInc

[Ron DiGiaimo @DigiaimoRon]

Please read and share. These are important facts. RCCS R3source Health: RCCS | Regents | RC Billing Americans for Fair Health Care

[Todd Scarbrough @toddscarbrough]

A new clinical trial at UT MD Anderson Cancer Center will test using low-dose radiation therapy to ease knee/hip osteoarthritis in people who have arthritis flares as a side effect of immunotherapy treatment for #breastcancer

https://t.co/4CARcIzwsg

[Ron DiGiaimo @DigiaimoRon]

Sad but true! This is PA by the way and Medicaid. There has been national disaster with regards to Medicaid! We MUST get them to recognize all these ridiculous rates before year end as the base rates were materially off to begin with. State regs limit increases so if the base rate is not corrected then we will have another year is disaster and some providers may start opting out of Medicaid, leaving the most vulnerable at risk and reduced access.

[Ron DiGiaimo @DigiaimoRon]

Lee Grossman
Medicaid Director
Iowa Department of Human Services
Iowa Medicaid
321 E. 12th Street
Des Moines, IA 50319

Re: Urgent Request to Update and Correct Medicaid Payment Rates for Radiation Oncology Services – CPT® Codes 77402, 77407, and 77412

Dear Medicaid Director:

I am writing to you in my capacity as Chairman of R3 and CEO of RC Billing with clients in Iowa to express grave concern regarding the current Iowa reimbursement rates for essential radiation oncology treatment delivery and guidance services. These outdated rates are unsustainable, severely undermine the financial viability of providing high-quality radiation therapy, and place timely access to care at serious risk for Iowa beneficiaries who require this life-saving treatment for cancer if these facilities are forced to halt services.

The rates for the revised radiation treatment codes are as follows:
· CPT 77402 (Radiation treatment, Level 1): $60.41
· CPT 77407 (Radiation treatment, Level 2): $70.96
· CPT 77412 (Radiation treatment, Level 3): $79.25

These rates are catastrophically low and do not come close to covering the actual costs of delivering safe, precise, and effective radiation therapy. Radiation oncology requires substantial capital investment in linear accelerators, imaging systems, quality assurance, physics support, and highly trained clinical staff. At these reimbursement levels, practices cannot absorb the ongoing operational expenses, leading to reduced capacity, delayed treatments, or complete discontinuation of services for Iowa patients in many communities. This directly jeopardizes patient outcomes in a vulnerable population that already faces barriers to care.
By comparison, national Medicare benchmarks for these same services (updated effective January 1, 2026, under the revised CPT coding structure that bundles technical image guidance into the delivery codes) are substantially higher and reflect the true resources involved:
· CPT 77402 (Level 1): approximately $79.49 (PFS non-facility) to $104.24 (HOPPS)
· CPT 77407 (Level 2): approximately $317.64 (PFS non-facility) to $394.05 (HOPPS)
· CPT 77412 (Level 3): approximately $391.46 (PFS non-facility) to $564.51 (HOPPS)
Iowa’s rates are lower than Medicare’s creating an untenable disparity. Many commercial payers reimburse at even higher levels. These national rates, while not extravagant, at least allow practices to maintain operations and invest in modern technology required for accurate, image-guided treatment.
The situation is urgent. Radiation therapy is a cornerstone of curative and palliative cancer care in which approximately 60% of cancer patients receive radiation therapy at some point in their treatment journey. Inadequate reimbursement threatens provider participation in Iowa networks, reduces geographic access (particularly in underserved areas), and risks poorer survival outcomes and increased downstream costs to the state from unmanaged disease progression.
We respectfully request that your appropriate team immediately review and align Iowa payment rates for CPT codes 77402, 77407, and 77412 with national Medicare benchmarks (or a reasonable cost-based equivalent) to ensure continued access to these critical services.
We are available to provide additional data, cost analyses, or meet with your team to discuss this matter promptly. Thank you for your immediate attention to this critical patient-access issue. We look forward to your response and collaborative action to protect Iowa beneficiaries’ access to radiation oncology care.
Sincerely,
Ron DiGiaimo MBA FACHE @OfficialRCCSInc

[Ron DiGiaimo @DigiaimoRon]

Perrie T. Briskin
Deputy Secretary of Healthcare Financing and Medicaid Director Maryland Medicaid Administration
State of Maryland, Department of Health
201 West Preston Street, Room 525
Baltimore, MD 21201
[email protected]

Re: Urgent Request to Update and Correct Medicaid Payment Rates for Radiation Oncology Services – CPT® Codes 77387, 77402, 77407, and 77412

Dear Deputy Secretary of Healthcare Financing and Medicaid Director:

I am writing to you in my capacity as Chairman of R3 and with clients in Maryland to express grave concern regarding the current Maryland reimbursement rates for essential radiation oncology treatment delivery and guidance services. These outdated rates are unsustainable, severely undermine the financial viability of providing high-quality radiation therapy.

The rates for the revised radiation treatment codes are as follows:

· CPT 77387 (IGRT): $38.29 for non-facility and $7.66 for facility

· CPT 77402 (Radiation treatment, Level 1): $85.35
· CPT 77407 (Radiation treatment, Level 2): $120.70
· CPT 77412 (Radiation treatment, Level 3): $139.45

These rates are catastrophically low and do not come close to covering the actual costs of delivering safe, precise, and effective radiation therapy. Radiation oncology requires substantial capital investment in linear accelerators, imaging systems, quality assurance, physics support, and highly trained clinical staff. At these reimbursement levels, practices cannot absorb the ongoing operational expenses, leading to reduced capacity, delayed treatments, or complete discontinuation of services for Maryland patients in many communities.

By comparison, national Medicare benchmarks for these same services (updated effective January 1, 2026, under the revised CPT coding structure that bundles technical image guidance into the delivery codes) are substantially higher and reflect the true resources involved:

· CPT 77387 (professional component only): approximately $36.74

· CPT 77402 (Level 1): approximately $79.49 (PFS non-facility) to $104.24 (HOPPS)

· CPT 77407 (Level 2): approximately $317.64 (PFS non-facility) to $394.05 (HOPPS)

· CPT 77412 (Level 3): approximately $391.46 (PFS non-facility) to $564.51 (HOPPS)

Maryland’s rates are lower than Medicare’s creating an untenable disparity.

The situation is urgent. Radiation therapy is a cornerstone of curative and palliative cancer care in which approximately 60% of cancer patients receive radiation therapy at some point in their treatment journey.

We respectfully request that your appropriate team immediately review and align Maryland payment rates for CPT codes 77387, 77402, 77407, and 77412 with national Medicare benchmarks (or a reasonable cost-based equivalent) to ensure continued access to these critical services.

Sincerely,

Ron DiGiaimo MBA FACHE RCCS R3source Health: RCCS | Regents | RC Billing @OfficialRCCSInc

[Oncology Brothers @OncBrothers]

We touched on 3 🔑 studies during our H&N Cancer and Melanoma Highlights from #ESMO26 w/ @AriRosenbergMD & @DrSapnaPatel

⭐️ #INTERpath001
⭐ #STARBOARD
⭐ #OrigAMI4

#OncTwitter #MedTwitter #hncsm

[Ron DiGiaimo @DigiaimoRon]

Please read and share

https://t.co/uFUZ0ajwWd I sit on the board of Americans for fair healthcare. These facts matter. @OfficialRCCSInc

[Ron DiGiaimo @DigiaimoRon]

Trying to confirm RVU AVG many Rad Oncs to published data, what in your estimated RVU:

[Ron DiGiaimo @DigiaimoRon]

Trying to confirm RVU AVG many Rad Oncs to published data, what in your estimated RVU:

[Oncology Brothers @OncBrothers]

Amivantamab (SC) now @FDA✅ for 2L R/M HNSCC (HPV-unrelated) post plat + IO based on #OrigAMI4:

- Ph1b/2, SC Ami mono (n=102)
- ORR 42% (CR 15%). Historic 2L ORR 20-25%
- mPFS 6.8mos, mOS 12.5mos
- DoR NR (56% ≥6mo)! Much needed option.

#OncTwittwer @OncUpdates @OncoAlert

[Oncology Brothers @OncBrothers]

“How do you pick your front line treatment option”? This question was asked by multiple different community colleagues.

@montypal: “There is no wrong answer…” and here is the data for IO/IO or IO-TKI in 1L metastatic #KidneyCancer

#GUSM #OncTwitter

[Ron DiGiaimo @DigiaimoRon]

@GavinNewsom Gavin can’t govern

[Ron DiGiaimo @DigiaimoRon]

@blackkracken @GavinNewsom Exactly

[Oncology Brothers @OncBrothers]

We touched on 5 🔑 studies during our GU Malignancies Highlights from #ESMO26 w/ @shilpaonc & @UroDocAsh

⭐️ #VOLGA
⭐ #DASLHICaP & #PROTEUS
⭐ #KEYNOTE564
⭐ #LITESPARK022

#OncTwitter #gusm @OncUpdates @myESMO

[Drew Moghanaki @DrewMoghanaki]

Did you know that up to 50% of all cancer diagnoses are made in the Emergency Department?

That statistic inspired this commentary, co-authored with Jonathan Goldman and two Emergency Medicine colleagues at UCLA, to examine the extraordinary opportunity Emergency Medicine clinicians have to offer hope for what today’s treatments can do that they couldn’t before.

It also grew out of many discussions with patient advocates, like @jillfeldman4, who has helped so many of us better understand how much the first words matter, both in what is said and how they are delivered, when a person hears for the first time: “you have lung cancer”.

https://t.co/wSRE654NE0